- £229.97m
- £113.94m
- $38.63m
- 47
- 12
- 27
- 16
Annual income statement for MaxCyte, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 26.2 | 33.9 | 44.3 | 41.3 | 38.6 |
| Cost of Revenue | |||||
| Gross Profit | 23.4 | 30.2 | 39.2 | 36.5 | 31.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 37.2 | 52.1 | 71.6 | 89.6 | 89.8 |
| Operating Profit | -11.1 | -18.2 | -27.4 | -48.3 | -51.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -11.8 | -19.1 | -23.6 | -37.9 | -41.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -11.8 | -19.1 | -23.6 | -37.9 | -41.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -11.8 | -19.1 | -23.6 | -37.9 | -41.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -11.8 | -19.1 | -23.6 | -37.9 | -41.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.17 | -0.211 | -0.232 | -0.367 | -0.392 |